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2 
Introduction  
 
Genetic testing has been facing an exponential growth in the last years. Further recent 
advances in molecular medicine are associated with even larger prospects and expected 
impacts on care management. When integrating these technologies into the healthcare 
system, it is important that their application is implemented within a responsible framework 
of accompanying measures and activities. As such, genetic testing has become also the 
subject of policy debates at different institutional and international levels.  
 
In order to help decision-makers at all levels to rapidly introduce the necessary 
requirements, the European Commission has organized a number of initiatives involving 
different services that follow the subject from different perspectives.  
 
Firstly, genetic testing currently falls under the scope of the Directive 98/79/EC of the 
European Parliament and of the Council on in vitro diagnostic medical devices. In the 
current system, patients, healthcare professionals and other interested parties do not have 
sufficient access to essential information on how medical devices have been assessed, and 
what clinical evidence there is to show they are safe and effective. After several procedures 
of consultation, on 26 September 2012, the  European Commission adopted a package on 
innovation in health consisting of the (a) Communication on safe, effective and innovative 
medical devices and in vitro diagnostic medical devices for the benefit of patients, 
consumers and healthcare professionals, (b) Proposal for a Regulation of the European 
Parliament and of the Council on medical devices, and amending Directive 2001/83/EC, 
Regulation (EC) No 178/2002 and Regulation (EC) N 1223/2009 and (c)  Proposal for a 
Regulation of the European Parliament and of the Council on in vitro diagnostic medical 
devices. 
This new text proposes to clarify and extent the scope of the IVD Directive on in vitro 
diagnostics, medical devices and clarifies the regulation of genetic tests. Target for its 
adoption is 2014 and the new rules would then gradually come into effect from 2015 to 
2019. 
 
Secondly, on 11 November 2008 the Commission Communication on Rare Diseases was 
adopted, that  sets out an overall Community strategy to support Member States in 
diagnosing, treating and caring for the 36 million EU citizens with rare diseases (1). This 
Communication focuses on three main areas: a) improving recognition and visibility of rare 
diseases, b) supporting policies on rare diseases in Member States for a coherent overall 
strategy, and c) developing cooperation, coordination and regulation for rare diseases at 
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EU level. As of rare diseases, there were several real and perceived obstacles to the 
transition from disease gene discovery to accessible, high-quality clinical laboratory testing, 
the major one being the perceived lack of financial incentives for individual laboratories to 
invest in the development and validation of a test with very low volume. In addition, genetic 
testing in research laboratories has significant issues related to access and quality of 
testing for this important group of disorders. Here the European cooperation aims to bring 
together the scarce resources for rare diseases fragmented across EU Member States and 
the European Commission works with the aim of promoting joint actions which may help 
patients and professionals to share expertise and information across borders. Quality 
management of diagnostic laboratories is one of the aspects discussed in the 
Communication. It recognizes that given the large number of tests and the need to design 
and validate a specific set of diagnostic assays for each, no single country can be self-
sufficient in the provision of testing and in an efficient external quality assessment of the 
provided tests. Therefore, there is a need to enable and facilitate the exchange of expertise 
through clearly stated, transparent, EU agreed standards and procedures of guaranteed 
quality and utility. 
Thirdly, the Council Recommendation on an action in the field of rare diseases was 
adopted on 8 June 2009 (2). The Recommendation engages the responsibility of Member 
States and concentrates on supporting and strengthening the adoption before the end of 
2013 of national plans and strategies for responding to rare diseases, on improving 
recognition and visibility of rare diseases, on encouraging more research into rare diseases 
and forging links between centers of expertise and professionals in different countries 
through the creation of European reference networks in order to share knowledge and 
expertise and, where necessary, to identify where patients should go when such expertise 
cannot be made available to them. The role of patients’ organizations is also highlighted as 
particularly important. Delegated and implementing acts will define the criteria to establish 
the methodology, including the process of selection and designation of the healthcare 
providers to be considered members of the European Reference Networks and several 
categories of criteria for the adequate management, monitoring and evaluation of the 
networks. One of the recommended areas to foster gathering the expertise on rare 
diseases at European level is the development of European guidelines on diagnostic tests 
or population screening, while respecting national decisions and competences. 
Fourthly,  the Directive 2011/24/EU on patients' rights in cross-border healthcare, clarifies 
rules regarding the right of patients to be treated outside their home country and 
reimbursed under certain conditions. Documents have specific provisions in regards to rare 
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diseases patients. The Directive will have no impact on the rights of each Member State to 
determine which health services they will provide. 
Fifthly, the European Commission Decision C (2009)9181 of 30 November 2009 formally 
established a European Union Committee of Experts on Rare Diseases (EUCERD) (3). 
This new structure, evoked in Point 7 of the Communication from the Commission to the 
European Parliament, the Council, the European Economic and Social Committee and the 
Committee of the Regions on Rare Diseases: Europe’s Challenges, adopted on 11 
November 2008, recommends that the European Commission be assisted by a European 
Union Advisory Committee on Rare Diseases: 
 
"The preparation and implementation of Community activities in the field of rare diseases 
require close cooperation with the specialised bodies in Member States and with the 
interested parties. Therefore, a framework is required for the purpose of regular 
consultations with those bodies, with the managers of projects supported by the European 
Commission in the fields of research and public health action and with other relevant 
stakeholders acting in the field." 
Thus, “the Committee acting in the public interest shall assist the Commission in 
formulating and implementing the Community’s activities in the field of rare diseases, and 
shall foster exchanges of relevant experience, policies and practices between the Member 
States and the various parties involved”. 
 
A number of documents and publications have been produced by the EUCERD and by 
other EC funded projects such as EUROPLAN (www.europlanproject.eu), which are of 
relevance for shaping collaboration on genetic testing between Member States and for 
defining points for action at EU level. Among those are: “Recommendations on Quality 
Criteria for Centers of Expertise for Rare Diseases in Member States” (4), “EUCERD 
Recommendations for European Reference Networks for Rare Diseases” (5), “State of the 
Art of Rare Disease Activities in Europe” (6), “Recommendations for the Development of 
National Plans for Rare Diseases” (7).  
 
In the light of these initiatives and the apparent need of expert input for further policy 
development European Commission’s Joint Research Centre in Ispra (Italy) in collaboration 
with EUCERD and the EC funded project Eurogentest (www.eurogentest.org) convened a 
workshop on 19-20 November 2012 in Ispra. The objective of the workshop was to provide 
expertise-based knowledge and views with regard to the quality and organization of genetic 
testing in Europe in order to support points of actions and decision-making initiatives at the 
research, clinical and policy levels. Furthermore, it aimed to explore future visions on the 
use, value and integration of genomic medicine into clinical practice. 
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The meeting received input from experts from European genetic testing laboratories; 
representatives of the Joint Research Centre, DG Research & Innovation,  and DG Sanco; 
clinical and laboratory geneticists; experts on quality management and external quality 
assessment; representatives of rare disease patients’ associations; representatives of 
national and/or international professional societies in genetics; experts in Health 
Technology Assessment; and experts in ethical, legal and social aspects of genetics and 
genomics.  
 
Considering the broadness of the field, the organizers decided to frame the scope of the 
workshop and provided the participants with six topics. Groups were formed and were each 
assigned a given topic to be discussed during interactive and bottom-up sessions. The goal 
of this set up was to stimulate expert perspectives in an open way. This approach provided 
opportunities for information to come forward through a process of discussion and 
interaction. This approach highlights commonalities in collective understanding and also the 
points at which perspectives differ. The outcomes of parallel sessions were then discussed 
at plenary meetings in the presence of all participants.  
 
The following six topics were discussed during the meeting:  
 
(1) Regional distribution of genetic services 
Nations - especially the smaller ones - cannot easily or reasonably offer all clinical and 
laboratory services for all rare diseases. Expertise is rare as well, especially when it is 
highly specialized. Hence, cross-border activities and international exchanges are a 
requisite, underlying the importance of national and international organization of rare 
disease networks, the organization of cross-border testing and the interoperable and 
federated knowledge-bases.  
 
(2) Suggestions for the rationalization of services 
Clinical geneticists and genetic services are primarily dealing with rare diseases. It has to 
be decided which genetic tests are useful and which are not. The plethora of offers needs 
to be assessed from a Health Technology and Health Care Provision viewpoint. This 
includes an analysis of the current genetic testing offer and its anticipated evolution, the 
analysis of clinical utility and the assessment of the needs for prioritization.  
 
(3) How to improve (national) accreditation of genetic laboratories? 
Accreditation is the best vehicle to ensure, assess and control quality in diagnostic testing. 
Accreditation is currently a matter that falls under the competence of national Member 
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States. In view of this, initiatives to support and promote quality assurance at the European 
level would be welcome. In particular, the exchange of knowledge and experience between 
Member States would be valuable, surely in relation to the fact that to obtain and maintain 
quality standards is a costly process. 
 
(4) (Long term) Organization of External Quality Assessment (EQA) 
Annual participation in EQA is an essential feature of the quality assurance in a laboratory 
and an obligation according to ISO norms for accreditation. EQA providers and scheme 
organizers must be equally subject to quality standards. 
 
(5) Validation of Next Generation Sequencing (NGS) platforms and applications 
The emerging ‘massive parallel sequencing’ technologies have revolutionized genetic 
research, and are increasingly applied in diagnostics. Initiatives are needed to validate 
those applications and to issue guidelines for the clinical application of exome sequencing 
and whole genome sequencing. Issues such as informed consent procedures, incidental 
findings, targeted versus exome versus total genome analysis, and 
interlaboratory/collaborative evaluation has to be addressed. 
 
(6) Perspectives on direct-to-consumer genetic testing 
In recent years various companies have started to advertise, sell or provide genetic tests 
directly to consumers. These companies cover a very broad spectrum of tests, including 
carrier tests for recessive genetic disorders, “life style”-related genetic traits, 
pharmacogenomics, genomic risk profiles for many conditions, paternity tests, and other 
relationship testing such as ancestry and invasive and non invasive prenatal paternity or 
gender tests. While the majority of the large companies are operating from the United 
States, the number of companies operating in Europe is increasing. This leads to the 
question which governance systems should be in place to deal with this emerging offer of 
genetic tests outside the healthcare system. Some Member States have considered these 
issues, for example in the UK, through the "Human Genetic Commission".  
 
This final report which provides an overview of all inputs gathered during the meeting and 
feedback received after circulation of a draft report should be considered as the result of a 
cross-fertilization exercise in which experts from different backgrounds and different areas 
were able to share their knowledge, concerns and views on necessary measures to be 
taken.The final outcome of this meeting is an overview of points of action which we hope 
will be taken into account by all stakeholders involved in the development, implementation 
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and monitoring of future initiatives addressing  the organization and quality of genetic 
testing in Europe.  
 
1- Organization of genetic testing for rare diseases in Europe 
  
The organization of genetic testing services in European countries follows different models 
due to the differences in the healthcare structure, due to the way clinical genetics 
developed historically as a specialty or not, and due to the level of development of basic 
research in human genetics.  
According to data from Orphanet (www.orphanet.com), the number of laboratories 
providing clinical tests is not proportional with the size of the population to serve and the 
scope of tests they offer varies widely between countries, somewhat in proportion with the 
size of the population but also according to a west-east geographical gradient. The exact 
number of diseases for which there is a test available at the country level can be found in 
the 2012 report on the state of art of rare disease activities in Europe of the EUCERD (6). 
These numbers do not reflect the number of tests which are accessible to the citizens of a 
given country. Some countries routinely purchase tests abroad, while for other countries, 
this may be impossible, for financial reasons. Some countries have bilateral agreements, 
which handle the purchase of tests from one country to another (Germany and Austria, for 
instance); in other countries, specific regulations for the reimbursement of genetic testing 
abroad are in place (Belgium and Portugal, for instance). The size of the cross- border 
testing activity is not exactly known. The last report on it can be found in the OECD 
Guidelines for Quality Assurance in Molecular Genetic Testing (8). 
The balance between private and public laboratories differs widely between countries as 
well, with a majority of private (albeit social security contracted) laboratories in Germany for 
instance, and none in the UK where currently the activity is normally embedded in the 
National Health System. The commercial offer increases rapidly at world level. It becomes 
hard to know where the testing activity is really performed as many companies subcontract 
their tests without releasing this information. The number of laboratories which are already 
accredited and/or participating to EQA schemes is quite different from one country to 
another. The funding process is quite different as well, genetic tests being considered as 
other types of tests and listed on the purchase list (fee schedule) with a defined price in 
some countries, while other countries provide a global budget to their diagnostic centers to 
run the activity. Finally genetic testing is regulated by law in some countries like France or 
Portugal, by professional guidelines in others like UK, or by law and professional guidelines 
as in Germany.  
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 This disparity of situations is a contribution to the inequity of access to 
genetic testing across Europe which request corrective measures by 
policymakers. 
 
Points for action: 
- Document the differences in the organization of genetic testing services to help identify 
where the specific bottlenecks are for each type of organization, which is preventing 
equitable access to tests and provide a basis for discussion between MS on ways to 
improve their own system; 
- Ensure that MS include provision for trans-border testing in their national plan; 
- Ensure that undiagnosed patients with RD have timely access to newly developed NGS 
diagnostic testing services as clinically appropriate and when available at national level. 
The access to laboratories providing NGS should be ensured within European Reference 
Networks for RD when appropriate.  
 
Genetic tests are generally considered as costly investigations the utility of which is not 
always perceived favorably when it comes to test for rare diseases. Clinical utility refers to 
the ability of a genetic test to significantly affect the clinical setting and patient outcome. A 
major challenge is to balance clinical validity, clinical utility and cost-benefit issues. In some 
cases a test is performing superbly in the laboratory, but is not viable from the economical 
point of view. On the other hand, some tests are limited in their validity, but nevertheless 
have great impact on patient and family management. Therefore it is important that the 
requirements for a test are defined in the context of their impact on the clinical setting and 
that the laboratory genetic test is only one of the components of an overall evaluation. 
Clinical Utility Gene Cards have been developed in the context of EuroGentest (9) to 
enable quick guidance to all stakeholders, including clinicians, geneticists, referrers, service 
providers and payers. Many care providers look only at the price of a test when deciding to 
reimburse or not, or when allowing for getting a test from another institution, when the price 
has to be appreciated in relation with the overall quality of the test and its suitability for the 
specific purpose, as often commercial companies offer look cheaper when compared to 
academic offer, but have a narrower scope (fewer mutations, exons and/or genes analysed, 
and no complementary techniques, such as MLPA or TP-PCR in appropriate cases), 
having therefore a lower relevance.  
 
 Economic constraints impose the consideration of all possible scale economies 
and prioritization of services on the basis of patient needs, cost/efficiency and 
evidence of clinical utility   
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Points for action: 
- Support the development of the evidence of the clinical utility of tests as part of the care 
pathway, in a collaborative manner, based on the experience of countries which have 
already developed initiatives in this area (such as Germany, France and the UK), and 
disseminate widely this information to health care providers and decision makers. Post this 
information in Orphanet, EuroGentest website, national institutional websites (e.g. MoH and 
their scientific bodies) and any other relevant information portal and disseminate it to 
appropriate third parties to ensure that reimbursement is linked to clinical utility; 
- Support the establishment of an EU/international registry of genetic tests with evidence-
based claims, including those to be offered by DTC genetic testing companies;. 
- Promote the appropriate use of genetic testing and the allocation of resources to genetic 
tests with clinical utility only. Referrals for genetic testing should better comply with the 
recommendations produced when generating evidence for the assessment of the clinical 
utility. If so, the number of tests performed will decrease significantly as the inappropriate 
use of genetic test has been well documented and subrogated against. This measure is not 
to limit the autonomy of the physicians but to guide them;. 
- Document in the Orphanet databases the price of the tests and the scope of the testing 
offered (techniques used and scope of investigated mutations). This will provide the ground 
for selecting the most cost/efficient laboratories when having to order a test abroad; 
- Support an increase in the health economy evaluation of genetic tests. 
 
The evolution of technology will very soon permit the incorporation of NGS into clinical 
laboratory activities. Among the many challenges generated by NGS, the interpretation of 
genomics data is the most burning one. Interpretation requires an expert knowledge both of 
the genomics field but also of the specialized medical field to which the disease of the 
investigated patient belongs. Networking between experts and between laboratories and 
clinical centres has emerged gradually these last years and proved to be very efficient in 
boosting research and improving clinical care and appropriate use of resources. In addition 
pooling of data generated by sequencing must be organized and encouraged in order to 
provide evidence allowing the interpretation of variants for the benefit of patients, as quickly 
as possible.  
 
 The right level of organization to maximize resources and expertise is the 
European, not the national one. The organization of the collaboration between 
expert laboratories should be set within the context of the European Reference 
Networks (ERNs), as described in the cross border directive. These networks 
should be specialized in a subset of RD corresponding to a subspecialty field.    
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Points for action: 
- Recommend to ensure access to a laboratory performing NGS in any ERN if relevant for 
the disease group in question, and include all the laboratories offering test for this group of 
diseases; 
- Recommend to provide these ERNs with a set of services, to be organized at European 
level, to support their activity, including support services and support tools for the 
governance, the legal and ethical requirements and for the informatics; 
- Ease early translation of genomics discoveries into quality services. This requires 
agreement on when a technology is sufficiently developed and validated enough to be used 
in a clinical setting, an issue of particular importance with NGS. Professional guidelines 
should be developed in support of the use of new diagnostic testing methods; 
- Ensure bridging between research data and clinical data by supporting the development of 
knowledge engineering. Make use of all open source tools already developed in Europe, 
like e.g. by Gen2Phen; 
- Ensure that clinical data are available for research purposes; at the minimum, aggregated 
data should be released, including by private laboratories; 
- Recommend principles under which to operate when establishing databases including 
phenotype and genotype data to ensure interoperability 
 
 
2- Quality Assurance  
2.1- Accreditation of laboratories 
Over the past decades, the international quality standards for demonstrating the technical 
competence of medical laboratories (ISO15189) have been issued and refined, that deal 
with the provision of laboratory services. Specific points of interest are e.g. that test and 
methods have to be analytically and clinically validated before they are offered for 
diagnostics, and that an interpretation of a technical result is an integral and necessary part 
of a genetic laboratory report. (8, 10, 11) 
Laboratories thus put quality assurance systems in place to improve the quality of their 
services and to warrant patient safety. The ISO standards, used for accreditation, also 
focus on the technical competence of the laboratory and the professionals involved in 
diagnostics. It is accepted that good quality systems result in better services, even without 
external evaluation. However, the external evaluation (e.g. by an external quality 
assessment scheme, recognized national accreditation bodies) of a laboratory service is a 
requisite if one wants to ensure the quality and safety of diagnostic services for patients, 
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compare the quality among laboratories, and enable equity of access and standardization 
of services over an entire sector (12, 13)  
Accreditation bodies are established in many countries with the primary purpose of 
ensuring that conformity assessment bodies are subject to oversight by an authoritative 
body. 
Those accreditation bodies, that have been evaluated by peers as competent, sign 
arrangements that enhance the acceptance of products and services across national 
borders, thereby creating a framework to support international trade through the removal of 
technical barriers. These arrangements are managed by the International Laboratory 
Accreditation Cooperation (ILAC), in the field of laboratory and inspection accreditation, and 
the International Accreditation Forum (IAF), in the fields of management systems, products, 
services, personnel and other similar programs of conformity assessment. Both 
organizations, ILAC and IAF work together and coordinate their efforts to enhance the 
accreditation and the conformity assessment worldwide. 
Accreditation is a national matter, and there is only one recognized national accreditation 
body (NAB) in each country that assesses laboratories against internationally agreed 
standards (Regulation (EC) No 765/2008). The European cooperation for Accreditation 
(EA, http://www.european-accreditation.org) a non-profit association, is the European 
network of the recognized NABs located in the European geographical area. One of its 
purposes is to develop and promote accreditation criteria and guidelines that will ensure 
harmonized performance of national accreditation bodies throughout the European 
economic area. ILAC is the international umbrella organization that covers all national and 
regional accreditation organizations. In principle, it is not the laboratory or an institute per 
se that is accredited, but the tests are included in the so-called ‘scope for accreditation’. 
This scope is published for the respective laboratories by the national accreditation bodies. 
 
A study conducted by EuroGentest in 2012 (13) in 31 European countries has revealed that 
23 % of the surveyed genetic testing laboratories were inspected by official accreditation 
bodies and a further 26% were certified. Notably, the accredited laboratories were located 
in only 12 different countries. This survey was the first large comprehensive update of the 
quality status in European genetic testing laboratories since the European projects on 
quality assurance were initiated in the early 2000s and literature was published that aimed 
to improve the quality in genetic testing. The previous study had been conducted in 2003 
and included 15 European countries and US (14).  An exact comparison cannot be made, 
but a quick look at the Orphanet/EuroGentest database suggests that only 183 out of 1645 
(11.1%) laboratories providing testing for rare diseases are effectively accredited and that 
544 (33%) of them participated in at least one EQA in 2011. It is generally accepted that 
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EU-sponsored projects like e.g. CRMGEN, CF-Network and especially EuroGentest, have 
significantly promoted accreditation. Hence, the fact that only a small minority of the 
laboratories are effectively accredited reveals that significant hurdles exist on the road 
towards accreditation. These include the mere fact that the installation of a quality system 
and the subsequent maintenance of it, in combination with regular external control schemes 
and the audits by the accreditation bodies, cost time, effort and money. Moreover, 
laboratories may not see or be aware of the advantages of being accredited, as long as 
other laboratories can continue to offer similar services without taking that extra burden. In 
some Member States, accreditation is – or will soon become – a requisite for the provision 
and/or reimbursement of genetic diagnostic tests. This requirement definitely provides an 
impetus for laboratories and institutes to move forward and invest in quality, and should 
become the norm in all Member States. 
 
 It is necessary to ensure the quality of the genetic diagnostic laboratories, for the 
sake of the patients and the benefit of the community. However, the wish to offer 
quality and peer pressure does not seem to drive the laboratories towards 
accreditation. The only way forward is to make accreditation the norm, i.e., that all 
diagnostic laboratories in Europe should be accredited. To further guarantee 
equity, regulation should include the requirement for all methods used in genetic 
testing to be within the scope of accreditation. Practical solutions do exist to deal 
with the case of extremely rare and thus low volume tests. 
 
However, several problems exist or become apparent: 
- Preparing for accreditation costs money, and in general, the national health care systems 
do not ‘reward’ laboratories for the extra costs. On the contrary, in many countries, the 
reimbursement rates for genetic tests have been or may soon be reduced, under economic 
constraints. 
- In general, bigger laboratories (higher number of personnel and higher number of samples 
received) were more likely to be accredited than smaller laboratories, even though, in 
principle, size per se should not be a hurdle or impediment (13). Some very small 
laboratories may not be able to redeem the effort or the costs to establish a quality system 
and go for accreditation. Such laboratories should perhaps close their doors, because if 
they are too small to cope with formal quality requirements, they are probably not fit for 
offering genetic testing at all. Nevertheless, for some very rare diseases, it is possible that 
only one or a few (often academic or research) laboratories in Europe (or even in the world) 
offer a specific test. Such laboratories would be identifiable through the ERNs for rare 
diseases. 
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 Some laboratories may be eligible for help in bearing the costs and achieving the 
transition towards accreditation. A transition period could be proposed, with 
specific funding for that transition. 
 
Some of the national accreditation bodies have difficulties to gear up towards auditing the 
genetic laboratories. The lead assessors need to accustom themselves with this new field, 
but more critically, more specialized technical experts are needed to evaluate the services 
on behalf of the accreditation body. In all EU countries, National Accreditation Bodies 
(NAB) are non-for-profit organizations that work under direct supervision of National 
Authorities. Hence, the national governments have to warrant that sufficient funds and 
people are available to provide good technical assessment. In general, the burden of an 
accreditation is significant, but the costs for the audits, i.e. the formal visits by the auditors 
and experts, are only a fraction of the total costs that the establishment and the 
maintenance of a quality system entail.  
 
 Governments may have to put mechanisms in place to alleviate the costs of the 
audits, for the laboratories as well as for the NABs. Measures have to be taken and 
systems have to be put in place to warrant that the accreditation requirements are 
equivalent in all instances.  
 
An EA Working Group for laboratory medicine meets every 6 months. All the issues related 
to one specific field are discussed with the ad hoc stakeholders. EuroGentest is the 
representative for human genetics, and other stakeholders could be added, if necessary. 
Nevertheless, specific guidelines for the evaluation and accreditation of specialized 
methods and novel technologies are needed. They have to be generated with the expert 
input from laboratory specialists, manufacturers, quality managers and representatives of 
the accreditation bodies. 
 
 The ISO norm provides a basis for harmonization but interpretation by experts may 
still vary. It would be good to increasingly liaise with European Accreditation (EA) 
about this issue. 
 
All too often, research data are transferred directly to the medical file of a patient without 
passing through the ‘quality filter’ of a diagnostic service. This is a dangerous practice, that 
may put patients and families at risk, e.g. when carrier and prenatal testing is offered on the 
basis of results that have not been confirmed independently in a laboratorial diagnostic 
context. 
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Diagnostic laboratories, that use research results or involve research scientists to generate 
(part of) a report, are responsible for the quality of those data that are eventually included in 
the clinical report. In practice, this means that the diagnostic laboratory has to effectively 
check the data that are generated in a research laboratory, or preferably repeat the 
essential part of the analysis in the diagnostic viz. accredited context. Generic  Standard 
Operation Procedures (SOPs) are essential, however it has to be clear that the context may 
vary, and SOPs shall thus not provide an invitation to install a superficial system. 
 
 
Points for action 
- Clarify the ISO standard to laboratories, through training sessions, workshops and 
personal guidance 
- Facilitate the transit towards accreditation by encouraging the laboratory geneticists to 
share their interpretation of the norm and existing guidelines into the clinical practice. 
- Write guidelines to complement the general ISO standards. 
- Establish a link with EA to ensure the uniformity of the implementation of the norm and the 
adoption of guidelines. 
- Ensure that accreditation bodies are able to handle the requests of accreditation of 
genetics laboratories and propose to pool international experts to visit the laboratories 
together with the lead assessors. 
- Verify at the national level the norm that it is necessary to validate the tests and the data 
before using them in a clinical context. Research data should not be returned to patients or 
their physicians, unless they have undergone the same scrutiny in terms of analytical and 
clinical validation as the tests, offered by diagnostic laboratories. 
 
 
2.2- External Quality Assessment 
External quality assessment is a tool for monitoring the quality of the laboratories and an 
integral part of the Quality Assurance. Several organizations are offering these services to 
the laboratories, either at national or international level. The European Commission has 
fostered the development of international EQA schemes through different projects like, 
e.g.,EuroGentest, of which EMQN was a partner.  
 
Some current issues are: 
 
- Poor performers: there are laboratories which are repeatedly failing to perform well in the 
analysis and interpretation of the samples that are circulated by the EQA providers. EQA 
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providers identify those laboratories, but they can only try and invite the collaborators from 
those laboratories to participate in training programs, to improve their service. However, it 
seems to be very difficult to motivate those laboratories to effectively seek support, for 
several reasons. It is not within the remit of the EQA providers, nor of EuroGentest, nor of 
the ESHG, to reprimand those laboratories. This can only be done at the national level, 
either by the competent authorities, by the department of health or by the healthcare 
payers. Only in a few countries, such a feedback mechanism to address poor performance 
is yet effectively in place. Especially the  healthcare payers should be informed of the 
importance of accreditation in the provision of quality and safe services in genetic testing. 
They can make accreditation a requirement of the services which they will fund. This can 
be a powerful encouragement for compliance to EQA participation and improve 
performance.   
 
- Participation to EQA is voluntary, except for an accredited laboratory that is strictly 
obliged to participate in inter-laboratory comparison such as EQA schemes. External 
evaluation could be organized in different ways, but, in practice, EQA schemes are often 
the most convenient way. This, in combination with the fact that only a minority of the 
laboratories are accredited, results in a variable uptake of EQA among regions and 
laboratories. For most EQA schemes, the participation has been growing over the past 
years, and the laboratories engaged in EQA seldom withdraw. But a significant percentage 
of the laboratories does not participate at all (13).   
 
- Participation to EQA schemes is expensive. The ISO norm and the accreditation 
process insist on external assessment for as many different tests within the laboratory’s 
scope as possible, and this for the entire examination process including pre and post 
examination. Not all EQA providers offer schemes which cover the whole process.  The full 
costs of EQA are a combination of the price for the subscription to the scheme, as well as 
the processing and reporting time within the lab. It is part of the burden of quality assurance 
in general. Given that the laboratories are funded nationally, significant differences exist in 
the way that laboratories can cope with these costs and efforts. These costs associated 
with quality initiatives should be included in any laboratory's budget. 
 
Suggestions have been made to train people by offering the possibility to host the 
collaborators from the poorly performing labs in better established laboratories. However, 
this has not been very successful, not in the least to due to the stigmatization which is 
associated with such activities.   
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Laboratories could share and exchange samples. However, this is a low scale initiative that 
only partly deals with the problem of quality in the laboratory, and that is hampered by 
regulations on cross-border transfer of samples. 
 
Both national and international schemes exist. There are advantages and disadvantages 
associated with this situation: 
- The national schemes allow laboratories to report in their own language. To some extent, 
this is also possible for the international schemes. 
- For both the national and the international schemes, a certain critical mass is necessary to 
sustain the activity. Hence, scale is an issue that may affect the quality of the EQA provider 
per se. 
- International schemes are important for rare diseases, i.e. most countries would not be 
able to support such schemes except for the more frequent genetic diseases, and probably 
no country would be able to offer the complete panel.  
- Some governments have effectively approved specific schemes. This is only acceptable if 
the schemes have the same standards as the international, accredited scheme. It should 
not be a mere protective measure for a national activity.  For instance, since 2001 the 
National Centre for Rare Diseases (Istituto Superiore di Sanità), upon commitment by the 
Italian MoH, coordinates the National EQA schemes for public and private genetic 
laboratories, according to the international standards 
(http://www.iss.it/cnmr/tege/index.php?lang=1) (15, 16). 
 
At present, the international EQA providers seem to be financially break-even. This is partly 
due to the fact that they are embedded in existing (academic) structures and it is only 
possible because the organizers of the schemes as well as the assessors donate their time. 
As the schemes get bigger, this will become problematic. Also, hospitals and academic 
institutions start to ask about the ‘value’ of this voluntary work and may request the scheme 
organizers to reimburse the people for their work. The fear is that this will very soon 
undermine the quality and provision of EQA. One of the strengths of existing EQA schemes 
is that the assessors are working scientists who understand the technicalities of the tests 
and the requirements for reporting. This especially applies to the EQA providers that were 
fostered by EuroGentest.   
 EQA providers have to be accredited, to confirm the quality of their services.  
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Commercial EQA schemes do exist, and some EQA providers are capable of offering their 
services at a lower cost than that of the no-for-profit schemes. This is partly due to the fact 
that they run more basic schemes (e.g. genotyping only), and that interpretation of the lab 
reports is not commonly included in the evaluation. It is observed that the EQA schemes 
have an important educational role and help the laboratories not only to monitor their 
technical performance but also to improve the quality of their reports. 
 
 The evaluation of the interpretation of test results in laboratory reports by the 
scheme organizers and assessors should be mandatory. Efforts and support are 
needed to make the EQA schemes sustainable without increasing the financial 
burden on the laboratories. 
 
 
Currently, the fees include the costs for the preparation and distribution of the samples, the 
administration, the assessment by experts, and the organization of pilot schemes together 
with best practice meetings.  Each of these activities could be sponsored and/or centralized 
to reduce the expenses on behalf of the EQA providers. This would be a better option than 
to subsidize individual laboratories to cope with the costs of EQA.  
 
 For many laboratories, the costs for EQA are already too high. Ways to subsidize 
the activity of the EQA process should be explored, as it would lead to the 
reduction of the costs of the EQA participation.  
 
The uptake of EQA has to be promoted for quality monitoring and assurance in general. To 
deal with poor performances in particular, specific educational and regulatory measures 
have to be taken. 
 
 Ideally, the EU could issue regulation on uptake of EQA. 
   
 
 
Points for action 
- Establish a registry of EQA schemes where providers submit their data to monitor the use 
of the EQA schemes as well as the performance of the laboratories. Harmonizing and 
reporting should be made mandatory, to warrant the value of the registry. 
- Develop an offer of educational meetings and courses to help the laboratories to improve 
their quality. EuroGentest has developed such courses, however, funding is limited and the 
 
18 
project ends in 2013. Issue a directive or regulation to make the accreditation of EQA 
providers mandatory. 
- Make an analysis of the costs of the EQA schemes to identify those costs that could be 
borne by a central national or European agency or organization. The latter would alleviate 
the costs of participation in the schemes. Suggestions are the funding of pilot schemes and 
best practice meetings, logistic support to the generation, distribution and validation of 
samples, organization support for the assessment of the laboratory reports, etc.  
 
 
3- Next Generation Sequencing 
Targeted sequencing, exome sequencing and, to a lesser extent, whole genome 
sequencing, are frequently and increasingly used for research. Several laboratories are 
already offering targeted sequencing and exome sequencing (for targeted analysis) in a 
diagnostic context. 
 
 It is generally believed that the use of panels of genes, that allows for 
comprehensive testing for the genetically heterogeneous diseases, will pass the 
threshold for clinical utility. Exome sequencing and total genome analysis for 
unknown diseases remains a research activity for the time being.  
 
Opening the "exome" or "genome" is currently outside the scope of what most of the 
diagnostic laboratories should offer, both in terms of quality standards as well as in 
operational terms. Also, in most countries, a specific regulation for the reimbursement of 
such comprehensive exploration of an individual’s genome is not in place. A few 
laboratories in Europe have already been accredited for NGS applications, including exome 
sequencing (for targeted analysis), even if no clear guidelines or consensus criteria exist. 
 
 It is important to specify the role of NGS for diagnostics.  
Several applications exist that effectively empower the specialized medical care, not in the 
least for the rapid identification of the genetic defect for rare disease patients. The fact that 
the new and especially the targeted approaches create a possibility to save resources 
should be exploited. On the one hand, the targeted analysis of genes with a known and 
proven role in a specific disease, should be supported. Exome or total genome analysis 
may be used as a tool to generate such panels, on the condition that the sensitivity and 
specificity of this approach are acceptable from a diagnostic standpoint. 
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On the other hand, exome sequencing for the identification of novel genes and defects is 
currently outside the scope of what can reasonably be offered in a diagnostic context.  
The clinical utility of gene panels is a matter of discussion. It cannot be determined by the 
laboratories alone, it should be established by expert panels that include medical 
specialists as well as clinical and laboratory geneticists 
Incidental findings are a side-product of genomic approaches to genetic testing. However, 
the mere fact that they exist and will be encountered should not overly impede the 
introduction of NGS into diagnostics. The following considerations should be made, and 
actions should be taken accordingly: 
- The phenomenon of incidental findings is known in medicine, and in particular in radiology. 
Over the years, the radiologists have established procedure and guidelines for dealing with 
incidental findings, that are both accurate and flexible, and regularly updated as the 
technologies for imaging evolve. It is accepted though, that this issue of incidental findings 
is of a different order of magnitude in genetics, esp. if the entire exome or genome is 
scrutinized in a patient. 
 
 -  A ‘red list’ of genes and/or variants that disclose ‘high risk’ and potentially treatable 
genetic predisposition would be helpful to deal with incidental findings in practice. There is 
a consensus that, at this stage, there is no meaningful clinical use of low risk predictions 
and hence, these should in principle not be communicated to the patient. It is an aspect of 
consumer protection to warn the community against unnecessary medicalisation. The ‘red 
list’ would also be helpful to regulate a direct-to-consumer offer of total genome or exome 
sequencing, as the providers of such test could be requested to ‘flag’ abnormal results that 
belong to this list and be obliged to refer the consumer for medical follow-up.   
 
-  An informed consent is necessary for a genomic diagnostic approach. It should allow the 
patient to decide beforehand whether or not to receive information other than that related to 
the disease under investigation.  
 
- Opinions and regulations vary as to whether a clinician can overrule the patient’s or 
parents' opinion in case of severe risk alleles, e.g. highly penetrant cancer predisposition 
mutations.  
 
NGS can be used to screen for fetal aneuploidies. In those applications, the technology is 
applied to quantify and determine the respective contribution of DNA fragments from e.g. 
chromosomes 18 and 21 to the free fetal DNA, circulating in the maternal circulation. This is 
a technical achievement, rather than a conceptual shift. However, total exome or genome 
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sequencing to determine an individual’s complete genotype or predisposition to disease, is 
not a tool for neonatal, prenatal or population screening at this stage. Genetic counseling is 
a communication process, which deals with the occurrence, or risk of occurrence, of a 
genetic disorder in the family. The process involves an attempt by appropriately trained 
person(s) to help the individual or the family to understand the medical facts of the disorder 
and the options on how to deal with it.  
 
 Total genome or exome testing should not be offered without such counseling. 
 
Points for action 
- Produce guidelines for NGS sequencing in a diagnostic setting, including that the 
diagnostic specificity and sensitivity and the performance of these assays have to be 
determined, and minimal criteria have to be defined. This is important both from the 
standpoint of the laboratories, who have to ensure the quality of the service and the safety 
of the patient, and from the standpoint of the accreditation bodies, who need criteria 
according to which those NGS tests can be accredited in the laboratories. The latter is also 
important to guarantee quality and equity in cross border testing. 
-It is important to create a knowledge basis for the interpretation of unclassified variants 
(UVs) i.e. variants for which the clinical significance is initially uncertain. An appropriately 
accessible international and comprehensive data basing environment is a necessary tool to 
allow the laboratories to reliably analyze the data. 
- Gather data about the frequency of incidental findings, and about the attitude of patients 
and families towards such findings. Several project proposals have been filed, that deal 
with the aspects of data management and exchange, for research as well as for 
diagnostics. 
- The national health care systems should put the systems in place for the reimbursement 
of ‘gene panels’ with a clinical utility.  
- Aspects of and knowledge about the genetic constitution of an individual should be 
included in the proposal for an EU Regulation on consumer protection. 
- Produce guidelines on the use of clinical information from NGS sequencing in the 
diagnostic setting. In particular, work should be supported on how to clinically manage 
incidental findings information from NGS. This is something that needs to be dealt with at 
the European or even global level 
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4- Direct-to-consumer genetic testing 
 
In recent years various companies have started to advertise, sell or provide genetic tests 
directly to consumers.  
In view of the quality standards advanced by the Council of Europe’s Additional Protocol to 
the Convention on Human Rights and Biomedicine, concerning Genetic Testing for Health 
Purposes and the OECD Guidelines for Quality Assurance in Molecular Genetic Testing 
(17), the offer of genetic tests for health purposes directly-to-consumers has created 
various concerns. Firstly, there are significant concerns regarding the clinical validity and 
utility of various tests offered (18). Also in the context of carrier identification of autosomal 
recessive disorders, there are concerns with regard to clinical validity. Secondly, marketing 
strategies of such companies often overstate the predictive value of the tests advertised 
and overrate its potential health implications. - For most common complex disorders, 
genotype-phenotype associations are weak and selective genotypes bad or even 
misleading predictors with regard to the development of the phenotype. 
 Thirdly, the offer of genetic tests through the Internet by commercial companies runs the 
risk to disconnect these services completely from their usual embedding in a medically 
supervised context. The absence of medical supervision for most DTC tests may 
compromise or fail to foster patient health. However, medical supervision is not always a 
guarantee of quality of service provision. Some examples illustrate that some of these 
companies involve healthcare professionals. In this case impartial health advice might be 
compromised. Fourthly, testing of third parties, not having given or being incapable of 
giving informed consent becomes possible. Such testing will most often be at odds with 
best practice clinical guidelines. Other concerns with regard to the activities of DTC 
companies include the research activities of these companies performed on submitted 
samples and information without adequate informed consent or monitoring by a research 
ethics committee as well as the potential submission of samples without consent. 
 
 It would be a mistake, and ultimately an unsuccessful endeavour, to focus efforts 
on remedying the potential harms from DTC tests without considering the entire 
regulatory context.  
 
Without a system in which an upfront expert evaluation can be made with respect to the 
validity of genetic tests, it will be difficult if not impossible to make rational decisions about 
who can and should order the test and receive the results, and what claims are appropriate 
in advertising.  
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Points for action  
 
 
Information provision to health care professionals and the general public 
-Provide information to healthcare professionals and the general public that gives 
background on genetic testing and describes the provision of genetic testing services.  
-Underline that clinically validated and medically appropriate genetic tests are offered in 
clinical services for those that need them and that these are reimbursed by the healthcare 
system.  
-Make available the information about the limitations and concerns of the tests that are 
currently advertised, provided or sold through the internet.  
-Take initiatives to stimulate public education (e.g. at school) and education of healthcare 
professionals.  
Frameworks regarding the provision of genetic testing services 
-The embedding of genetic testing in a healthcare setting can ensure a context where due 
emphasis is being provided on the individualized medical supervision of patients, the 
presence of pre-test and post-test counseling, psychological evaluation and  follow-up if 
appropriate and quality assurance of the tests performed.  
-Analyze the legal models in place in some Member States in order to study the strengths 
and limitations of these approaches, and their potential for application in other Member 
States.  
Legal frameworks regarding the use of predictive health information in other 
contexts 
-Concerns have been raised regarding the use of personal predictive (genomic) health 
information by third parties, such as insurers or employers. It is necessary to study various 
existing legislations on this issue in the various Member States, in order to generate best 
practices for harmonization across European Union.  
Penalization of the submission of DNA samples of third parties without their consent 
-More efforts are necessary at a European level in order to sanction individuals that submit 
samples from a third person without his or her consent. Services through the internet are 
organized in such a way that there is no control over the origin of the samples being 
analyzed. Most companies send mouth swab kits as these are easier and more practical 
than having to send the client to a clinic where blood is drawn.  Since the mouth swab is 
done in the privacy of the clients’ home, there is no way of controlling for the identity of the 
sample provider.  
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The report has been drafted by Ayme, Borry, Gribaldo and Matthijs before being circulated 
to the participants. 
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Abstract 
The workshop was designed with the aim of bringing together experts and stakeholders in the field of genetic testing to discuss 
the (future) organization of genetic testing in Europe. Obviously since it is not be possible to adequately deal with all aspects of 
genetic testing within the framework of one workshop, a limited number of issues have been selected. The selection was based 
on the importance and urgency of the matter and the need and opportunity for action at the European level, and the likelihood for 
successful intervention. Primary deliverables of this workshop have been planned as to be able to define a vision on the use, 
value and integration of genomic medicine into clinical practice and to prepare a briefing note to highlight the specific points that 
deserve the Commission’s interest. Quality of genetic testing and organization of genetic testing services were the two main 
themes of the scope of the workshop. To warrant the quality of the genetic diagnostic laboratories the way forward is to make 
accreditation the norm, i.e. the diagnostic laboratories in Europe should be accredited. To further guarantee equity, the regulation 
should include the requirement for all tests to be within the scope accreditation. The embedding of genetic testing in a healthcare 
setting can ensure a context where due emphasis is being provided on the individualized medical supervision of patients, the 
presence of pre-test and post-test counseling, psychological follow-up if appropriate and quality assurance of the tests 
performed. In light of growing number of companies selling and advertising genetic tests, it is crucial that information is available 
for healthcare professionals and the general public that gives background on genetic testing and describes the provision of 
genetic testing services. 
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policies with independent, evidence-based scientific and technical support throughout the whole policy 
cycle. 
 
Working in close cooperation with policy Directorates-General, the JRC addresses key societal 
challenges while stimulating innovation through developing new standards, methods and tools, and 
sharing and transferring its know-how to the Member States and international community. 
 
Key policy areas include: environment and climate change; energy and transport; agriculture and food 
security; health and consumer protection; information society and digital agenda; safety and security 
including nuclear; all supported through a cross-cutting and multi-disciplinary approach. 
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